RCS - Creo Medical Group - Speedboat® patient testimonial

Creo MedicalAnnouncement

Mon 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250804:nRSD7311Ta&default-theme=true

RNS Number : 7311T  Creo Medical Group PLC  04 August 2025

Creo Medical Group plc

("Creo" or the "Company")

 

Speedboat® patient testimonial

 

Successful Speedboat® treatment for wife of Creo engineer underscores the
real-world impact of Speedboat® and the value of the ongoing Welsh health
board commercial pilot

 

Creo Medical Group plc (AIM: CREO), the Welsh based medical device company
focused on the emerging field of minimally invasive surgical endoscopy for
pre-cancer and cancer patients, has issued a testimonial video from a patient
who successfully underwent a procedure utilising Creo's Speedboat®
technology.

 

Liz Thomas, the wife of one of the Creo engineers who helped to develop the
innovative Speedboat® technology, faced a major health challenge in late 2024
and was told the only option available to her was a full bowel resection,
given that the Speedboat® procedure was not available through NHS Wales at
that time.

 

Liz's husband, a software engineer for Creo before his retirement, was aware
that Speedboat® could be a treatment option and sought a second opinion.
Opting to seek private treatment in England outside of the NHS, Liz was able
to benefit from an outpatient Speedboat® procedure and, as with so many
other patients in England through the NHS, avoided the removal of her bowel
and associated major surgery. She has made a successful recovery and
returned to daily life within days of the procedure, underscoring the
real-world impact of Speedboat® on quality of life.

 

Speedboat® continues to provide significant clinical value to a rapidly
increasing number of patients in the treatment of the early stages of
colorectal cancer avoiding complex and impactful surgery. In this, a typical
speedboat case, a 5cm pre-cancerous lesion was removed without stitches,
scarring, prolonged recovery, or post-operative long term health requirements.
This case, and the extensive data from many other cases undertaken worldwide,
demonstrates the ability of Speedboat® to reduce surgical burden, shorten
hospital stays, and improve patient outcomes.

 

The testimonial also highlights the significance of Aneurin Bevan University
Health becoming the first Health Board in Wales to pilot Creo's Speedboat®
technology, as announced in February 2025
(https://www.londonstockexchange.com/news-article/CREO/first-welsh-adopter-of-speedboat-r-technology/16888360)
. The pilot is already proving successful with patients in Wales already
treated since the procedure was made available in early 2025. The Company
believes the successful conclusion of the pilot, and supporting data, will
drive further adoption across other health boards in Wales, paving the way for
wider NHS rollout and supporting Creo's commercial growth strategy.

 

As adoption continues to grow across the UK and globally, Liz's experience
highlights the profound human impact of Creo's mission: transforming lives,
one procedure at a time.

 

The video interview can be found here:
https://www.creomedical.com/en/patients/patient-case-stories
(https://www.creomedical.com/en/patients/patient-case-stories)

 

For further information please contact:

 

 Creo Medical Group plc                                                        www.creomedical.com
                                                                               (https://protect.checkpoint.com/v2/___http:/www.creomedical.com/___.YzJ1OmludHVpdGl2ZTpjOm86NWJlYzBmMzJjY2MyZTBiZWFkNmJkZmVmNzdhM2MwMTI6NjoyYWU4OjczNzQyNWUwODBjYTEwNzAxYWMzNWEyZDQ3YzI1ZmEwYWMzYTc4M2Q2M2NjYzEyNTQwZWM3ODc4NTk3NTE4YTQ6cDpUOk4)
 Richard Craven, Company Secretary                                             Via Walbrook PR

 Deutsche Numis (Nominated Adviser, sole Broker and Financial Adviser)         +44 (0)20 7260 1000

 Freddie Barnfield / Duncan Monteith / Sher Shah

 Walbrook PR Ltd                      Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com (mailto:creo@walbrookpr.com)
 Paul McManus / Alice Woodings        Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

 

About Creo Medical

Creo Medical is a medical device company focused on the development and
commercialisation of minimally invasive electrosurgical devices, bringing
advanced energy to endoscopy.

 

The Company's vision is to improve patient outcomes through the development
and commercialisation of a suite of electrosurgical medical devices, each
enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA
powered by Kamaptive full-spectrum adaptive technology to optimise surgical
capability and patient outcomes. Kamaptive is a seamless, intuitive
integration of multi-modal energy sources, optimised to dynamically adapt to
patient tissue during procedures such as resection, dissection, coagulation
and ablation of tissue. Kamaptive technology provides clinicians with
increased flexibility, precision and controlled surgical solutions. CROMA
currently delivers bipolar radiofrequency ("RF") energy for precise localised
cutting and focused high frequency microwave ("MW") energy for controlled
coagulation and ablation via a single accessory port. This technology,
combined with the Group's range of patented electrosurgical devices, is
designed to provide clinicians with flexible, accurate and controlled clinical
solutions. The Directors believe the Company's technology can impact the
landscape of surgery and endoscopy by providing a safer, less-invasive and
more cost-efficient option for procedures.

 

For more information, please refer to the website www.creomedical.com
(http://www.creomedical.com)

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAEALPDEADSEFA